News
TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...
GlaxoSmithKline has staked a claim to the fast-moving category of cancer therapies targeting the TIGIT immune checkpoint, agreeing a $2 billion plus licensing agreement with iTeos Therapeutics for ...
GSK, iTeos TIGIT drug belrestotug shows efficacy in PD-L1-high NSCLC trial at ESMO, giving some positive news for the beleaguered class.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results